Benazepril (Lotensin)
benazepril hydrochloride
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults and children ≥6 years (GFR >30 mL/min) | Monotherapy or combination (especially with thiazides or CCBs) | FDA Approved |
Benazepril is FDA-approved solely for hypertension, making it among the more focused ACE inhibitors in terms of labelled indications. It is frequently used in fixed-dose combination with amlodipine (Lotrel) or hydrochlorothiazide (Lotensin HCT). The ACCOMPLISH trial (2008) demonstrated that the benazepril-amlodipine combination reduced cardiovascular events by 20% compared to benazepril-hydrochlorothiazide in high-risk hypertensive patients, supporting ACE inhibitor plus calcium channel blocker as a preferred combination strategy.
Heart failure with reduced ejection fraction (HFrEF) — ACE inhibitors are part of guideline-directed medical therapy (GDMT) per AHA/ACC 2022. Although specific benazepril HF trials are limited, the class effect is well established. Evidence: High (class level)
Diabetic nephropathy / proteinuric CKD — ACE inhibitors reduce proteinuria and slow CKD progression. Benazepril has dual renal-biliary elimination, which may be advantageous in moderate renal impairment. Evidence: High (class level)
Combination with amlodipine for CV risk reduction — Based on ACCOMPLISH trial data showing superiority of benazepril-amlodipine over benazepril-HCTZ for CV events. Evidence: High
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — not on a diuretic | 10 mg PO once daily | 20–40 mg/day | 80 mg/day | Give once daily or divide BID if trough effect wanes Onset: ~1 h; peak BP reduction: 2–4 h; effect persists 24 h (FDA PI) |
| Hypertension — already on a diuretic | 5 mg PO once daily | 20–40 mg/day | 80 mg/day | Discontinue or reduce diuretic before starting if possible; otherwise start at 5 mg with close monitoring |
| Hypertension — combination with amlodipine (ACCOMPLISH approach) | 10–20 mg PO once daily + amlodipine 5 mg | 20–40 mg + amlodipine 5–10 mg | 40 mg + amlodipine 10 mg | Fixed-dose combination available (Lotrel); amlodipine reduces benazepril-associated cough perception |
Pediatric Dosing (Age ≥6 Years, GFR >30 mL/min)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Hypertension — pediatric | 0.2 mg/kg PO once daily | Titrate as needed | 0.6 mg/kg/day (max 40 mg) | Not recommended <6 years or if GFR <30 mL/min Suspension can be compounded from 20 mg tablets (2 mg/mL) |
Renal & Hepatic Impairment
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CrCl >30 mL/min | No adjustment | Standard | 80 mg/day | PK similar to normal renal function (FDA PI) |
| CrCl ≤30 mL/min (or SCr >3 mg/dL) | 5 mg PO once daily | Titrate to response | 40 mg/day | Biliary clearance partially compensates for reduced renal elimination (FDA PI) |
| Hepatic impairment (cirrhosis) | No adjustment required | Standard | Standard | Benazeprilat PK essentially unaltered; however, caution with cirrhosis and ascites |
| Haemodialysis | 5 mg PO | Per response | 40 mg/day | ~6% benazeprilat removed in 4 hours of dialysis (FDA PI) |
Morning doses of benazepril provide more prolonged blood pressure control (~19 hours) compared to afternoon doses. For patients with suboptimal trough response on once-daily dosing, dividing into two equal daily doses or adding a diuretic is more effective than simply increasing the dose. Dose-proportional pharmacokinetics apply within the 10–80 mg range, but no data exist above 80 mg/day (FDA PI).
Pharmacology
Mechanism of Action
Benazepril is an oral prodrug that undergoes rapid hepatic ester cleavage to benazeprilat, a potent non-sulfhydryl ACE inhibitor. Benazeprilat competitively inhibits angiotensin-converting enzyme, preventing conversion of angiotensin I to angiotensin II. This reduces systemic vascular resistance, aldosterone secretion, and sodium-water retention while potentially increasing vasodilatory bradykinin levels. Single and multiple doses of 10 mg or more produce at least 80–90% inhibition of plasma ACE activity for at least 24 hours, supporting once-daily dosing. In haemodynamic studies, benazepril lowered blood pressure with reduced peripheral resistance, increased cardiac output and renal blood flow, and minimal change in heart rate. It has an antihypertensive effect even in patients with low-renin hypertension, though the effect is less pronounced in Black patients as monotherapy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ≥37% (urinary recovery); Tmax benazepril 0.5–1 h, benazeprilat 1–2 h; dose-proportional PK from 10–80 mg | Food does not affect extent of absorption but delays benazeprilat Tmax to 2–4 h; can be taken with or without food |
| Distribution | Protein binding: benazepril 96.7%, benazeprilat 95.3%; binding unaffected by age, hepatic dysfunction, or concentration | Highly protein-bound; crosses blood-brain barrier only to an extremely low extent |
| Metabolism | Almost complete hepatic cleavage of ester group to benazeprilat (active); further glucuronidation of both parent and metabolite; no CYP involvement | Hepatic cirrhosis slows conversion but does not alter overall benazeprilat bioavailability; minimal CYP interaction risk |
| Elimination | 37% of dose in urine (20% benazeprilat, 8% benazeprilat glucuronide, 4% benazepril glucuronide); biliary ~11–12%; effective t½ 10–11 h | Dual renal-biliary elimination; biliary route partially compensates in renal failure; steady state in 2–3 doses; ~6% removed by 4 h dialysis |
Side Effects
| Adverse Effect | Incidence (vs Placebo) | Clinical Note |
|---|---|---|
| Headache | 6% vs 4% | Most frequent adverse effect; similar to placebo rate; rarely treatment-limiting (0.6% DC rate) |
| Dizziness | 4% vs 2% | Usually transient; more common in first days of therapy or with concurrent diuretics |
| Cough | <1% (monotherapy); 3.3% (combination) | Class effect due to bradykinin accumulation; <1% difference from placebo in monotherapy trials; 3.3% vs 0.2% placebo in Lotrel combination trials; 0.5% DC rate; switch to ARB if intolerable |
| Somnolence | 2% vs 0% | Not commonly reported with other ACE inhibitors; may affect driving or operating machinery |
| Postural dizziness | 2% vs 0% | Higher risk with volume depletion or concurrent diuretics; advise rising slowly from seated/lying position |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Angioedema | ~0.5% | Any time during therapy; higher rate in Black patients | Discontinue immediately; secure airway; epinephrine if laryngeal involvement; never rechallenge with any ACE inhibitor |
| Acute renal failure | Rare | Days to weeks; bilateral renal artery stenosis is highest risk | Discontinue benazepril; IV volume resuscitation; evaluate for renovascular disease |
| Hepatic failure / cholestatic jaundice | Very rare | Variable | Discontinue; urgent hepatology referral; monitor for jaundice and liver enzyme elevations |
| Neutropenia / agranulocytosis | Rare | Weeks to months; collagen vascular disease + renal impairment = highest risk | Monitor WBC in high-risk patients; discontinue if confirmed |
| Stevens-Johnson syndrome / pemphigus | Very rare (post-marketing) | Variable | Immediate discontinuation; dermatology referral |
| Fetal toxicity | Expected with 2nd/3rd trimester exposure | Second and third trimesters | Discontinue immediately when pregnancy detected; fetal monitoring |
Cough with benazepril is less prominently featured in the FDA PI than with other ACE inhibitors, with only a 0.5% discontinuation rate in hypertension monotherapy trials. However, in longer-term combination trials (Lotrel), the rate was 3.3% vs 0.2% placebo, consistent with the ACE inhibitor class effect. As with all ACE inhibitors, cough is dry, non-productive, and caused by bradykinin accumulation. If intolerable, switching to an ARB is the standard approach.
Drug Interactions
Benazepril is activated by hepatic ester cleavage, not CYP enzymes. The FDA PI confirms no clinically important PK interactions with hydrochlorothiazide, furosemide, chlorthalidone, digoxin, propranolol, atenolol, nifedipine, amlodipine, naproxen, or cimetidine. Key risks relate to additive RAAS blockade, potassium homeostasis, and renal haemodynamics.
Monitoring
- Blood PressureEach visit; closely after initiation
RoutineAssess peak (2–6 h) and trough (pre-dose) responses. In HF patients, monitor for first 2 weeks and after dose increases. - Renal FunctionBaseline, then periodically
RoutineSerum creatinine and electrolytes. Monitor more frequently with concurrent NSAIDs, renal impairment, or volume depletion. - Serum PotassiumPeriodically
RoutineRisk of hyperkalaemia increases with renal impairment, diabetes, or concurrent K-sparing agents. - WBC / DifferentialIf high-risk
Trigger-basedConsider in patients with collagen vascular disease and/or renal impairment. Advise patients to report infection signs. - Hepatic FunctionIf symptoms develop
Trigger-basedMonitor for jaundice or signs of liver failure; ACE inhibitors rarely associated with cholestatic hepatitis. - Pregnancy StatusBefore starting and ongoing
RoutineConfirm negative pregnancy test in women of childbearing potential. Counsel on reliable contraception.
Contraindications & Cautions
Absolute Contraindications
- History of angioedema with or without previous ACE inhibitor treatment, or hereditary/idiopathic angioedema
- Hypersensitivity to benazepril or any ACE inhibitor
- Pregnancy (discontinue immediately when detected)
- Concurrent aliskiren in patients with diabetes mellitus
- Concurrent neprilysin inhibitor (e.g., sacubitril/valsartan); 36-hour washout required
Relative Contraindications (Specialist Input Recommended)
- Bilateral renal artery stenosis or stenosis of a solitary kidney
- Haemodynamically significant aortic stenosis
- Collagen vascular disease with renal impairment — insufficient data to exclude agranulocytosis risk
Use with Caution
- Volume depletion or hyponatraemia — correct before starting; consider 5 mg initial dose
- Elderly patients — likely decreased renal function; start at lower doses and monitor
- Renal impairment (CrCl ≤30) — dose reduction required; monitor renal function closely
- Heart failure with low BP (<100 mmHg systolic) — increased hypotension risk; start under supervision
- Patients <6 years of age — safety and efficacy not established; infants <1 year at risk of renal damage
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, benazepril should be discontinued as soon as possible. Second and third trimester exposure is associated with fetal renal dysfunction, oligohydramnios, skull hypoplasia, and neonatal death.
Patient Counselling
Purpose of Therapy
Benazepril helps lower blood pressure by blocking a hormone system that tightens blood vessels. Controlling blood pressure reduces the risk of stroke, heart attack, and kidney damage. Benazepril does not cure high blood pressure but controls it when taken consistently every day. Do not stop taking benazepril without discussing with your prescriber, even if you feel well.
How to Take
Take benazepril at the same time each day, preferably in the morning for optimal 24-hour coverage. It can be taken with or without food. If a dose is missed, take it as soon as remembered unless the next dose is due soon. Never double up.
Sources
- Lotensin (benazepril hydrochloride) tablets prescribing information. Validus Pharmaceuticals. Revised 2015. FDA LabelPrimary regulatory source for approved indications, dosing, adverse reactions, pharmacokinetics, and renal impairment adjustments.
- Lotrel (amlodipine besylate and benazepril hydrochloride) capsules prescribing information. Revised 2017. FDA LabelFixed-dose combination label; source for benazepril bioavailability (≥37%), combination adverse event rates, and angioedema incidence (~0.5%).
- Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients (ACCOMPLISH). N Engl J Med. 2008;359(23):2417–2428. doi:10.1056/NEJMoa0806182Demonstrated 20% relative risk reduction in CV events with benazepril-amlodipine vs benazepril-HCTZ in high-risk hypertensive patients.
- Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency (AIPRI). N Engl J Med. 1996;334(15):939–945. doi:10.1056/NEJM199604113341502Demonstrated benazepril slowed progression of chronic renal insufficiency, supporting off-label use in proteinuric CKD.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–e115. doi:10.1161/HYP.0000000000000065Major hypertension guideline supporting ACE inhibitors as first-line for compelling indications including HF and CKD.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063Positions ACE inhibitors as part of GDMT for HFrEF; supports class-level use of benazepril in heart failure.
- Balfour JA, Goa KL. Benazepril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs. 1991;42(3):511–539. doi:10.2165/00003495-199142030-00008Comprehensive early review of benazepril pharmacology, efficacy, and tolerability from initial clinical development.
- Sica DA, Marino MR, Engles G. Benazepril: a review of its pharmacokinetics. Cardiovasc Rev Rep. 1991;12:16–22.Detailed PK overview covering absorption, protein binding (96.7%/95.3%), dual renal-biliary elimination, and renal impairment effects.
- Kaiser G, Ackermann R, Dieterle W, Dumont E, Eckert HG. Pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol. 1990;38(4):379–385. doi:10.1007/BF00315579Elderly PK study showing 20–40% higher benazeprilat Cmax and AUC with ~20% reduction in renal clearance.
- Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med. 1998;128(12 Pt 1):982–988. doi:10.7326/0003-4819-128-12_Part_1-199806150-00004Supporting evidence for ACE inhibitor renoprotection in diabetic patients; class-relevant to benazepril use in nephroprotection.
- Benazepril. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated October 5, 2024. NCBI BookshelfComprehensive updated review covering pharmacology, dosing, adverse effects, and current clinical considerations.